Document 0657
 DOCN  M95A0657
 TI    Treatment review. 
 DT    9510
 SO    Treat Rev. 1995 Mar/Apr;(no 17):8. Unique Identifier : AIDSLINE
       AIDS/95700326
 AB    A number of studies are being conducted for HIV infections and
       opportunistic infections; these studies involve both new drugs and drugs
       currently in use, although administered differently or used for less
       traditional diseases. The studies include use of 1) foscarnet for
       treatment of early Kaposi's sarcoma; 2) tecogalen, an angiogenesis
       inhibitor, for more advanced Kaposi's sarcoma; 3) thalidomide for HIV
       infections, mouth ulcers, and wasting associated with HIV infection; 4)
       interleukin-2 for HIV infection; 5) testosterone for loss of sex drive
       secondary to depression in HIV infection; and 6) prozac for treating
       depression in HIV infection. Information is also given on a Spanish
       forum on approved and experimental treatments for AIDS and HIV. For
       further information on any of these studies, contact the Network at
       (800)734-7104.
 DE    AIDS-Related Opportunistic Infections/DRUG THERAPY  Adult  Cachexia/DRUG
       THERAPY  Clinical Trials  Depression/DRUG THERAPY/*THERAPY  Female
       Fluoxetine/THERAPEUTIC USE  Foscarnet/*THERAPEUTIC USE  HIV
       Infections/*DRUG THERAPY/THERAPY  Human  Interleukin-2/*THERAPEUTIC USE
       Male  Neovascularization/*DRUG THERAPY  Sarcoma, Kaposi's/BLOOD
       SUPPLY/*DRUG THERAPY  Stomatitis, Aphthous/DRUG THERAPY
       Testosterone/THERAPEUTIC USE  Thalidomide/*THERAPEUTIC USE  NEWSLETTER
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).